Cover Image
市場調查報告書

自體免疫注射劑市場

Autoimmune Injectables to 2020

出版商 Greystone Research Associates 商品編碼 304991
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
自體免疫注射劑市場 Autoimmune Injectables to 2020
出版日期: 2014年06月04日 內容資訊: 英文
簡介

僅管解明了多樣的疾病及疾病群的基本疾病的機制,自體免疫狀態大部分治療方法依然難以解決治療困難。自體免疫症狀的發生和嚴重性中,由於根底上存在各種遺傳的多樣性,自體免疫治療藥的市場上地區多樣性非常廣泛。此多樣性,由於有關於治療方案及文化背景的差異,該地區的企業編制聯盟或聯盟關係日益重要。在過去2年中,新性能改善的自體免疫疾病治療用注射劑的市場投入,對醫生和患者來說產生出新的選項。

本報告提供全球自體免疫注射劑市場相關研究、免疫疾病調節的機制、自體免疫疾病的治療相關現狀、各疾病種類自體免疫疾病的治療方法分析彙整、自體免疫注射劑的市場預測、法規情形、聯盟與夥伴關係等商業環境,以及主要企業簡介等彙整資料,為您概述為以下內容。

摘要整理

疾病治療的免疫疾病調節

  • 疾病發展和人類健康的模式
  • 疾病的發生,治療及預防的免疫疾病反應
  • 免疫疾病的連鎖
  • 受體、配體及細胞信號傳達途徑

自體免疫疾病的治療:商業性現實

  • FDA認證藥物
  • 患者及疾病的人口動態
  • 競爭環境
  • 規定成長的要素
  • 法規要素
  • 每服用成本和管理護理
  • 副作用、加框警語和病人依從性

自體免疫疾病的治療:疾病區分分析

  • 關節炎
  • 乾癬
  • 多發性硬化症
  • 克隆氏症
  • 紅斑性狼瘡

自體免疫注射劑:適應症、市場資料、預測

  • TNF
  • 成長阻礙因素
  • 白細胞介素
    • 干擾素(interferon)
  • T細胞受體抑制劑
  • 自然地免疫疾病細胞受體抑制劑
  • 激化酵素抑制劑
  • 補助刺激分子抑制劑
  • 趨化素受體
  • 轉錄因子
  • 血管黏合抑制劑
  • 類鐸受體
  • 其他免疫疾病學的因素藥物候補

商務因素

  • 法規因素
    • 臨床試驗通訊協定、終點
  • 聯盟、夥伴關係

自體免疫注射劑:企業簡介

目錄
Product Code: AJR252K

In spite of the growing understanding of the underlying disease mechanisms for a host of diseases and disease families, autoimmune conditions continue to be intractable to most therapies and difficult to treat. Because of the individual genetic variability underlying the incidence and severity of autoimmune symptoms, regional variations in the market for autoimmune therapeutics can be significant. This variability is compounded by differences in treatment protocols and cultural factors, which combine to make alliance partnerships with regional players of increasing importance. Over the past two years the introduction of new and improved injectables for treating autoimmune diseases is creating new options for clinicians and patients. This optimism is being reinforced by pipeline candidates that will further the effort to improve treatment protocols for patients.

Highlights

  • Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential
  • Assesses existing and evolving immune disease mechanisms, treatment strategies and pipeline drug candidates
  • Provides data and forecasts for major autoimmune disease segments to 2020
  • Evaluates regional and global opportunities for autoimmune therapeutics

Table of Contents

Executive Summary

Immune Modulation in Disease Therapeutics

  • Evolving Models of Disease and Human Health
  • The Immune Response in Disease Incidence, Treatment & Prevention
  • The Immune Cascade
  • Receptors, Ligands and Cell Signaling Pathways

Autoimmune Disease Therapeutics- Commercial Realities

  • FDA-Approved Drugs
  • Patient and Disease Demographics
  • Competitive Landscape
  • Factors Limiting Growth
  • Regulatory Factors
  • Cost per Dose and Managed Care
  • Side Effects, Black Box Warnings and Patient Compliance

Autoimmune Disease Therapeutics - Disease Segment Analysis

  • Arthritis
  • Psoriasis
  • Multiple Sclerosis
  • Crohn's Disease
  • Lupus

Autoimmune Injectables - Indications, Market Data and Forecasts

  • TNF
  • Growth Factor inhibitors
  • Interleukins
    • Interferons
  • T-Cell Receptor Inhibitors
  • Innate Immune Cell Receptor Inhibitors
  • B-Cell Receptor Inhibitors
  • Kinase Inhibitors
  • Co-stimulator Inhibitors
  • Chemokine Receptors
  • Transcription Factors
  • Vascular Adhesion Inhibitors
  • Toll-like Receptors
  • Other Immune Factor Drug Candidates

Business Factors

  • Regulatory Factors
    • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships

Autoimmune Injectables- Company Profile

Back to Top